In the first phase 3 trial to show the superiority of a TROP2-targeted antibody-drug conjugate and an immunotherapy agent in ...

In the Phase III DESTINY-Breast09 trial, Enhertu (trastuzumab deruxtecan) and Perjeta (pertuzumab) significantly improved ...

AstraZeneca and Daiichi Sankyo are aiming to establish their star antibody-drug conjugate (ADC) Enhertu as a first-line ...

The data could help the Enhertu regimen overtake a drug combination that’s been used as the initial treatment for ...

AstraZeneca's Enhertu shows significant success in late-stage trials as a first-line treatment for HER2-positive metastatic ...

AstraZeneca AZN will report its first-quarter 2025 earnings on April 29, before market open. The Zacks Consensus Estimate for ...

Thousands attended the Abu Dhabi Global Health Week Conference, where Iskra Reic, the EVP of International at AstraZeneca, ...

As the 2020 pandemic became a distant memory and millions of Americans returned back to their old lives, some were left ...

British pharmaceutical giant AstraZeneca signed a landmark agreement earlier this month to invest $2.5 billion in Beijing over the next five years, demonstrating confidence in the capital's ...

Aping the rhetoric of Elon Musk’s Department of Government Efficiency in the US, Labour’s Health Secretary Wes Streeting ...

Critics say this violates the principle of shareholder democracy and makes it harder for investors to hold boards to account.

China’s response to new United States (U.S.) tariffs could complicate the supply of important medicines, an analysis of data ...